Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways
El-Agamy, Dina S., El-Harbi, Khaled M., Khoshhal, Saad, Ahmed, Nishat, Elkablawy, Mohamed A., Shaaban, Ahmed A., Abo-Haded, Hany M.Volume:
Volume 11
Langue:
english
Journal:
Cancer Management and Research
DOI:
10.2147/CMAR.S186696
Date:
December, 2018
Fichier:
PDF, 3.89 MB
english, 2018
File converter
Plus de résultats de recherche
More benefits 
